Quotient is a commercial-stage diagnostics company committed to increasing efficiencies and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and donor disease screening (transfusion diagnostics), Quotient is developing MosaiQ™, its next generation automation platform to address the comprehensive needs of the global transfusion diagnostics market. Once approved for sale, MosaiQ will be the first fully automated solution for blood grouping, quickly and comprehensively characterizing both donor and patient blood, improving patient outcomes and eliminating the need for expensive and time-consuming manual testing. MosaiQ will also undertake all mandated serological disease screening tests required for donor blood. Quotient has over 30 years of experience developing, manufacturing and commercializing transfusion diagnostic products. The company’s operations are based in Switzerland, Scotland and the US.
19 June 2019
Amazing team and great product!
What works well?
Huge team spirit and excellent working atmosphere! Very nice people and mind set. Quotient product is an amazing one and it generates a very passionate working environment focused on business and innovation.
What could be improved?
Quotient Suisse is still in a pre-product selling situation (like in a start-up situation) and can't yet invest a lot in people development. This may change when MosaiQ will be on the market. (comment written in June 19)